INNOVENT BIO (01801) partner OLLIN BIOSCIENCES and its next-generation ophthalmology pipeline are to be acquired
Innovent Biologics (01801) announced that its partner Ollin Biosciences, Inc. (Ollin) has entered into an acquisition agreement with Johnson & Johnson (NYSE: JNJ). Ollin's core pipeline asset OLN324 (Innovent's development code: IBI324) was developed by Innovent and out-licensed.
INNOVENT BIO (01801) announced that its partner Ollin Biosciences, Inc. (Ollin) has entered into an acquisition agreement with Johnson & Johnson (NYSE: JNJ). Ollin's core pipeline asset OLN324 (INNOVENT BIO development code: IBI324) was developed and out-licensed by INNOVENT BIO.
Founded in 2023, Ollin aims to discover and accelerate the development of next-generation ophthalmology therapies. Its core pipeline asset OLN324 is a bispecific antibody targeting VEGF and Ang2 that is undergoing global Phase III clinical trials. Following molecular structure optimization and potency optimization, it is intended for the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). These two severe retinal vascular diseases are among the leading causes of blindness worldwide, affecting more than 40 million patients globally. Leveraging its differentiated molecular design and clinical data obtained to date, OLN324 has the potential to achieve more effective resolution of retinal fluid and extend dosing intervals. Recently, OLN324 has initiated patient enrollment in global Phase III clinical trials for the above two indications.
Over the past few years, the company has worked closely with the Ollin team to jointly advance the clinical development of OLN324/IBI324. Retinal vascular diseases affect tens of millions of patients worldwide, and the shared goal of both parties is to develop this drug candidate into a novel treatment option with clinical value. The company is pleased to witness this important milestone for its partner, and the drug candidate has the potential to achieve stronger and more durable disease controla potential recognized by a leading global pharmaceutical company. The company will continue to work with all partners to fully advance project development and bring benefits to patients with retinal vascular diseases worldwide as soon as possible.
Related Articles

BAIGE DIGITAL (02672) is taking steps to initiate legal proceedings in the relevant Chinese courts against the relevant persons and/or entities in respect of the relevant matters.

US Stock Market Move | Optical communication concept stocks fall broadly in pre-market trading; POET Technologies (POET.US) drops over 8%.

REGAL PARTNERS (01575): Proposed Adoption of New Share Option Scheme and Conditional Grant of Share Options
BAIGE DIGITAL (02672) is taking steps to initiate legal proceedings in the relevant Chinese courts against the relevant persons and/or entities in respect of the relevant matters.

US Stock Market Move | Optical communication concept stocks fall broadly in pre-market trading; POET Technologies (POET.US) drops over 8%.

REGAL PARTNERS (01575): Proposed Adoption of New Share Option Scheme and Conditional Grant of Share Options






